BaroFold CEO to Chair Panel Regarding Biologics and Drug Development Challenges: 'Novel Approaches to Protein Aggregation and Production' at the BIO International Conference.BOULDER, Colo. -- BaroFold, Inc. announced today that Dr. Lyndal Hesterberg, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , will be chairing the panel discussion as part of the Biologics and Drug Development Challenges section: "Novel Approaches to Protein Aggregation and Production" at the Biotechnology Industry Organization's International Convention. Industry experts from research and product development, including Brent Kendrick, Ph.D., Amgen, Jorg Thommes, Ph.D., Biogen Idec Biogen Idec, Inc. (NASDAQ: BIIB) is a biotechnology company specializing in drugs for neurological disorders, autoimmune disorders and cancer. The company was formed in 2003 by the merger of Cambridge, Massachusetts-based Biogen and San Diego, California-based Idec and John Carpenter, Ph.D., University of Colorado Health Sciences Center The University of Colorado Health Sciences Center (UCHSC) is part of the University of Colorado System. It has recently been merged with the University of Colorado at Denver (UCD) to form the University of Colorado at Denver and Health Sciences Center. , will provide their perspectives on their experiences and discuss creative problem solving Creative problem solving is the mental process of creating a solution to a problem. It is a special form of problem solving in which the solution is independently created rather than learned with assistance. Creative problem solving requires more than just knowledge and thinking. for protein therapeutic development, scale-up and production. Dr. Carpenter is one of the inventors of high pressure technology. Efforts to address immunogenicity immunogenicity /im·mu·no·ge·nic·i·ty/ (-je-nis´it-e) the property enabling a substance to provoke an immune response, or the degree to which a substance possesses this property. and protein aggregation challenges in bioprocessing of clinical product will also be described. The BIO International Convention will be held May 6-9, 2007 at the Boston Convention and Exhibition Center The Boston Convention and Exhibition Center (BCEC) is the largest exhibition center in the Northeast United States, with some 1,700,000 square feet (15.8 hectare) of contiguous exhibition space. . The panel discussion is scheduled for 11:00 am, Wednesday, May 9, 2007, in Room 205B. Lyndal Hesterberg, Ph.D., is President, CEO and a founder of BaroFold. He has managed technology development and commercialization in the biotechnology field for over 20 years. He has previously held senior positions with Amgen, BioStar, SomaLogic, and Syngene. About BaroFold BaroFold is a fully integrated bio-therapeutics company. BaroFold's PreEMT[TM] technology enables improved, safer, proprietary protein therapeutics, providing product life-cycle extensions and creating new protein therapeutics through the use of a patented protein refolding technology. PreEMT[TM] involves the use of high hydrostatic pressure to disaggregate See disaggregated. and refold Re`fold´ v. t. 1. To fold again. proteins. The protein production process incorporating high pressure can result in significant final product manufacturing savings per dose compared to conventional methods, while providing the patentable basis for a safer drug with fewer aggregates in the product formulation. The method is simple, reliable, and is operating on an industrial scale. BaroFold is currently in development with its own proprietary protein therapeutic portfolio. In addition to advancing its own proprietary therapeutics, BaroFold is also developing select improved protein therapeutics in partnerships with other biotechnology and pharmaceutical companies. For additional information about the company, please visit http://www.barofold.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion